ACCEL Lite: Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For HFrEF | ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research Podcast

ACCEL Lite: Vulnerable Plaques: Vascular Biology Update: The causes of heart attacks are shifting in this era of better control of cholesterol, blood pressure, and smoking and fewer instances of fatty plaque rupturing and causing blood clots. But a different cause of clots seems to be on the rise:... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Asymptomatic Severe AS; Outcomes of Early Intervention: In this interview, Spencer King III, MD, MACC; Michael Reardon, MD; and Michelle Kelsey, MD, discuss the natural history of asymptomatic severe aortic stenosis and the association of early intervention with outcomes. For 20+ insider interviews like... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: ESC Congress 2021 Late Breaker: IAMI: In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: ESC Congress 2021 Late-Breaker: TOMAHAWK: In this interview, Michelle Kittleson, MD, FACC, and Steffen Desch, MD, discuss the ESC Congress late-breaker TOMAHAWK, which examined whether immediate coronary angiography in survivors of out-of-hospital cardiac arrest and no ST-segment elevation is... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

9 min listen

ACCEL Lite: Strategies to Maximize Doses and Introduce New Medication: As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

19 min listen

$ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be...$

ACCEL Lite: CardioNutrition - A Mediterranean Dietary Pattern: This week we bring you a sample of the CardioNutrition program airing on ACC’s CardiaCast podcast. Enjoy! The recent prevention guideline from the American College of Cardiology recommends that all adults should consume a healthy diet that... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: The Challenge of Telemedicine: Increasing Utilization Without Robust Data: Telemedicine use has surged over the past year, and this may pose a risk to the quality of care if standards aren't applied to its practice and use. In this interview, Alison Bailey, MD, FACC; Jeff Wessler, MD, MPhil, FACC; and Estefania Oliveros, MD,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: HRS Late Breaker: LBB-Optimized CRT: In this interview, Andrea Russo, MD, FACC; Marek Jastrzebski, MD, PhD; and Jeffrey Hsu, MD, PhD, focus on a Heart Rhythm Society late-breaking study on LBB optimized CRT, discussing its differences from traditional pacing and benefits to the patient,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Contraception and Reproductive Planning for Women with Cardiovascular Disease: As the number of women of childbearing age with heart disease grows, the importance of safe and effective birth control counseling for pregnancy planning is more important than ever. Which contraceptive methods are optimal for women with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Clinical Utility and Age-Related Challenges of CV Imaging in Older Patients: Geriatric principles impact the utility, performance, and interpretation of CV imaging tests. Considering geriatric principles can improve the patient experience during CV testing and the application of test results to clinical care. In this... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: ACC.21 Late Breaker: The ATLANTIS Trial: The ATLANTIS trial will change the way antithrombotic treatments are chosen after successful transcatheter aortic valve implantation. In this interview, Roxana Mehran, MD, FACC; Jean-Philippe Collet, MD; and Zaid I. Almarzooq, MBBCh, discuss anti-xa... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Innovations in Remote Patient Monitoring: What Can it Bring to My Practice?: Personalizing care in the digital world has always been a challenge because of administrative burden and interoperability issues. The future is already here and we have the chance to leverage remote patient monitoring properly to engage patients with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: ESC Congress 2021 Late Breaker: EMPEROR-Preserved: In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes: This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Low-Flow, Low-Gradient AS: When Is it Severe?: Severe aortic stenosis may go unrecognized, and therefore untreated, in the setting of a low gradient, even if all data point to the existence of a low-flow, low-gradient state and a severe degree of stenosis. In this interview, Mirvat Alasnag, MB,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Rural Electrification is the New Deal: We need to close the gap in urban versus rural response times, and the time to defibrillation is the critical question. What unique challenges do rural communities face, and how was this compounded over the last year by COVID? In this interview,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Universal Definition of HF Syndrome: Evolving Strategies: The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: What Should Optimal Medical Therapy Look Like Prior to Intervention?: It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Impact of PCI on Outcomes in Patients With HF: Observational studies suggest a benefit with PCI in patients with HF, but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking. In this interview, Roxana... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Screening for Transthretin Amyloid Cardiomyopathy in Everyday Practice: TTR amyloidosis is increasingly recognized as a cause of diastolic heart failure and as much more common than previously thought. There are proven and investigational therapies that can slow or possibly stop this disease. In this interview, Rodney H.... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

16 min listen

ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction: Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all. In this interview, Stephen J. Greene, MD... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

$ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you...$

ACCEL Lite: Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL: Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Should You “Aspirin” in Older Adults With Subclinical Atherosclerosis?: In this interview, Kim Williams MD, MACC; John William “Bill” McEvoy, MB, BCh, MHS; and Michelle Kelsey, MD, discuss whether to use aspirin for primary prevention in adults >70 years old with subclinical atherosclerosis. Like what you hear? Get... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Amiodarone Monitoring in 2021: Amiodarone monitoring: are existing guidelines outdated? In this interview, A. John Camm, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Tiffany Y. Hu, MD, discuss Amiodarone monitoring in 2021. Like what you hear? Get 20 episodes/month... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Rhythm Control vs. Rate Control in Patients With HF and High Burden AF: Atrial fibrillation and heart failure coexist in many patients; what is the best management plan for them? In this interview, Uma Narasimhan Srivatsa, MBBS, FACC; Anthony Tang, MD; and Anthony J. Mazzella, MD, discuss RAFT-AF (A Randomized... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research